INmune Bio Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 21

Employees

  • Stock Symbol
  • INMB

Stock Symbol

  • Share Price
  • $1.04
  • (As of Friday Closing)

INmune Bio General Information

Description

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 225 Northeast Mizner Boulevard
  • Suite 640
  • Boca Raton, FL 33432
  • United States
+1 (561)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Stock Exchange
NAS
Corporate Office
  • 225 Northeast Mizner Boulevard
  • Suite 640
  • Boca Raton, FL 33432
  • United States
+1 (561)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

INmune Bio Stock Performance

As of 13-Nov-2026, INmune Bio’s stock price is $1.04. Its current market cap is $32.5M with 31M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.04 $1.05 $1.01 - $2.60 $32.5M 31M 328K -$0.60

INmune Bio Financials Summary

As of 30-Sep-2026, INmune Bio has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 37,114 14,819 72,906 174,023
Revenue 0 50 14 155
EBITDA (16,419) (45,849) (41,293) (27,730)
Net Income (16,666) (45,933) (42,082) (30,008)
Total Assets 21,508 32,351 39,562 57,001
Total Debt 1,210 1,034 384 10,437
Public Fundamental Data provided by Morningstar, Inc. disclaimer

INmune Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore INmune Bio‘s full profile, request access.

Request a free trial

INmune Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its pr
Drug Discovery
Boca Raton, FL
21 As of 2025

Boston, MA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

INmune Bio Competitors (83)

One of INmune Bio’s 83 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Boston, MA
ImmunityBio Formerly VC-backed San Diego, CA
Redx Pharma Venture Capital-Backed Macclesfield, United Kingdom
Adimab Venture Capital-Backed Lebanon, NH
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 83 competitors. Get the full list »

INmune Bio Patents

INmune Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250321234-A1 Method for detecting anti-drug antibodies against self-assembling trimeric biologics using an affinity capture elution-protein a/g assay Pending 16-Apr-2024
AU-2025232756-A1 Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization Pending 08-Mar-2024
WO-2025189204-A2 Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization Pending 08-Mar-2024
WO-2025189204-A3 Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization Pending 08-Mar-2024
WO-2025189204-A8 Stabilized dn-tnf mutein bioconjugates for selective soluble tnf neutralization Pending 08-Mar-2024 A61K47/60
To view INmune Bio’s complete patent history, request access »

INmune Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

INmune Bio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view INmune Bio’s complete esg history, request access »

INmune Bio FAQs

  • When was INmune Bio founded?

    INmune Bio was founded in 2015.

  • Where is INmune Bio headquartered?

    INmune Bio is headquartered in Boca Raton, FL.

  • What is the size of INmune Bio?

    INmune Bio has 21 total employees.

  • What industry is INmune Bio in?

    INmune Bio’s primary industry is Drug Discovery.

  • Is INmune Bio a private or public company?

    INmune Bio is a Public company.

  • What is INmune Bio’s stock symbol?

    The ticker symbol for INmune Bio is INMB.

  • What is the current stock price of INmune Bio?

    As of 13-Nov-2026 the stock price of INmune Bio is $1.04.

  • What is the current market cap of INmune Bio?

    The current market capitalization of INmune Bio is $32.5M.

  • Who are INmune Bio’s competitors?

    Aura Biosciences, ImmunityBio, Redx Pharma, Adimab, and Immunocore Holdings are some of the 83 competitors of INmune Bio.

  • What is INmune Bio’s annual earnings per share (EPS)?

    INmune Bio’s EPS for 12 months was -$0.60.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process